A Functional Biological Marker is Needed for Diagnosing Magnesium Deficiency

Journal of the American College of Nutrition

Volumn 23, Issue 6, 2004, Pages 738S-741S

  Franz, Kay B ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Biomarker; C reactive protein; Endothelin 1; Magnesium; Na K ATPase; Thromboxane B2

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALCOHOL; ASCORBIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CAROTENE; COENZYME A; CYANOCOBALAMIN; ENDOTHELIN 1; FERRITIN; FOLIC ACID; HEMOGLOBIN; HOMOCYSTEINE; IRON; MAGNESIUM; METHIONINE; METHYLMALONIC ACID; PYRIDOXINE; SELENIUM; THROMBOXANE B2; TRANSFERRIN RECEPTOR;

CONFERENCE PAPER; ENDOTHELIUM LESION; HEMATOCRIT; HUMAN; MAGNESIUM DEFICIENCY; MEAN CORPUSCULAR VOLUME; NONHUMAN; THROMBOCYTE; THROMBUS;

ADENOSINE TRIPHOSPHATASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENDOTHELIN-1; HUMANS; MAGNESIUM DEFICIENCY; NUTRITIONAL STATUS; THROMBOXANE B2;

ANIMALIA;

EID: 11844262765     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2004.10719418     Document Type: Article

References (34)

1. Potischman N, Freudenheim JL: Biomarkers of nutritional exposure and nutritional status: an overview. J Nutr 133: 873S-874S, 2003.
2. Hambidge M: Biomarkers of trace mineral intake and status. J Nutr 133: 948S-955S, 2003.
3. Mason JB: Biomarkers of nutrient exposure and status in onecarbon (methyl) metabolism. J Nutr 133: 941S-947S, 2003.
4. Dorup I: Effects of K, Mg2 deficiency and adrenal steroids on Na, KO-pump concentration in skeletal muscle. Acta Physiol Scand 156: 305-311, 1996.
5. Nadler JL, Buchanan T, Natarajan R, et al: Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 21: 1024-1029, 1993.
6. Guerrero-Romero F, Rodriguez-Moran M: Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord 26: 469-474, 2002.
7. Kramer JH, Mak IT, Phillips TM, Weglicki WB: Dietary magnesium intake influences circulating pro-inflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress. Exp Biol Med (Maywood) 228: 665-673, 2003.
8. Gao S, Chen Z, Xu Y: Plasma endothelin and atrial natriuretic peptide in normal and hypertensive pregnancy. Chin Med J (Engl) 109: 823-826, 1996.
9. Lacapere JJ, Bennett N, Dupont Y, Guillain F: pH and magnesium dependence of ATP binding to sarcoplasmic reticulum ATPase. Evidence that the catalytic ATP-binding site consists of two domains. J Biol Chem 265: 348-353, 1990.
10. Patchornik G, Goldshleger R, Karlish SJ: The complex ATPFe(2) serves as a specific affinity cleavage reagent in ATPMg(2) sites of Na, K-ATPase: altered ligation of Fe(2) (Mg(2)) ions accompanies the E(1)3E(2) conformational change. Proc Natl Acad Sci USA 97: 1954-11959, 2000.
11. Lechi C, Corradini P, Polignano R, et al: Measurement by bioluminescence technique of erythrocyte membrane Na, K-ATPase activity in hypertensive patients. Clin Chim Acta 163: 329-337, 1987.
12. Mattiasson I, Berntorp K, Lindgarde F: Insulin resistance and Na /KO-ATPase in hypertensive women: a difference in mechanism depending on the level of glucose tolerance. Clin Sci (Lond) 82: 105-111, 1992.
13. Martinez FJ, Sancho-Rof JM: Epidemiology of high blood pressure and obesity. Drugs 46: 160-164, 1993.
14. Rabini RA, Petruzzi E, Staffolani R, et al: Diabetes mellitus and subjects' ageing: a study on the ATP content and ATP-related enzyme activities in human erythrocytes. Eur J Clin Invest 27: 327-332, 1997.
15. Okegbile EO, Odusan O, Adeola O: Erythrocyte membrane digoxin-sensitive (NaO-K)-ATPase of non-insulin dependent diabetic humans. Biosci Rep 17: 499-506, 1997.
16. Scarpini E, Bianchi R, Moggio M, et al: Decrease of nerve Na, KO-ATPase activity in the pathogenesis of human diabetic neuropathy. J Neurol Sci 120: 159-167, 1993.
17. Mimura M, Makino H, Kanatsuka A, et al: Reduction of erythrocyte (NaO-K)ATPase activity in type 2 (non-insulindependent) diabetic patients with microalbuminuria. Horm Metab Res 26: 33-38, 1994.
18. Shechter M, Merz CN, Paul-Labrador M, et al: Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardio 84: 152-156, 1999.
19. Shechter M: The role of magnesium as antithrombotic therapy. Wien Med Wochenschr 150: 343-347, 2000.
20. Nigam S, Averdunk R, Guenther T: Alteration of prostanoid metabolism in rats with magnesium deficiency. Prostaglandins Leukot Med 23: 1-10, 1986.
21. Chavarria ME, Lara-Gonzalez L, Gonzalez-Gleason A, et al: Prostacyclin/ thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol 188: 986-992, 2003.
22. Hishinuma T, Tsukamoto H, Suzuki K, Mizugaki M: Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications. Prostaglandins Leukot Essent Fatty Acids 65: 191-196, 2001.
23. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H: Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167: 73-79, 2003.
24. Sattar N, Gaw A, Scherbakova O, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108: 414-419, 2003.
25. Cao JJ, Thach C, Manolio TA, et al: C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 108: 166-170, 2003.
26. Ford ES, Mokdad AH, Giles WH, Brown DW: The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 52: 2346-2352, 2003.
27. Tjoa ML, Van Vugt JM, Go AT, et al: Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immunol 59: 29-37, 2003.
28. Mak IT, Stafford R, Weglicki WB: Loss of red blood cell glutathione during Mg deficiency: prevention by vitamin E, Dpropranolol, and chloroquine. Am J Physiol 267(5Pt1): C1366-C1370, 1994.
29. Nohria A, Garrett L, Johnson W, et al: Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension 42: 43-48, 2003.
30. Minami S, Yamano S, Yamamoto Y, et al: Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension. Hypertens Res 24: 663-670, 2001.
31. Nakamura T, Suzuki S, Ushiyama C, et al: Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure. Acta Cardiol 57: 19-21, 2002.
32. Schneider JG, Tilly N, Hierl T, et al: Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 15: 967-972, 2002.
33. Ferri C, Bellini C, Desideri G, et al: Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes 105: 38-40, 1997.
34. Slowinski T, Neumayer HH, Stolze T, et al: Endothelin system in normal and hypertensive pregnancy. Clin Sci (Lond) 103: 446S-449S, 2002.